| Date Filed | Type | Description |
| 10/13/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/11/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/11/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/21/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 08/07/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 08/07/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/07/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/26/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/08/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/05/2023 |
4
| Cote Timothy R. (Director) has filed a Form 4 on SOLIGENIX, INC.|
Txns:
| Granted 15,000 options to buy
@ $1.42, valued at
$21.3k
|
|
| 05/05/2023 |
3
| Cote Timothy R. (Director) has filed a Form 3 on SOLIGENIX, INC. |
| 05/04/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 05/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 05/01/2023 |
8-K
| Quarterly results |
| 04/19/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 04/19/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/24/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 02/14/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Soligenix intends to seek guidance from the FDA on how to further advance HyBryte ™ towards potential approval Princeton, NJ – February 14, 2023 – Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States Food and Drug Administration has provided the Company with a Refusal to File letter for its HyBryte™ new drug application in the treatment of early stage cutaneous T-cell lymphoma , a rare cancer and area of unmet medical need affecting over 25,000 patients in the U.S. Upon preliminary review, the FDA determined that the NDA, submitted on December 14, 2022, was not sufficiently complete to permit substantive review. Soligenix fir..." |
|
| 02/09/2023 |
8-K
| Quarterly results |
| 01/11/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/11/2023 |
8-K
| Other Events Interactive Data |
| 01/06/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 12/27/2022 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 12/27/2022 |
8-A12G
| Form 8-A12G - Registration of securities [Section 12(g)]: |
| 12/23/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 12/23/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 12/19/2022 |
8-K
| Quarterly results |
|